News

404

Immunophotonics Announces 1st Patient Dosed in Multinational Clinical Trial in the United Kingdom

SACHS Forum and ASCO Annual Meeting in Chicago June 2 – 6, 2023

Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Chicago at the SACHS 9th Annual Immuno-Oncology Innovation Forum, June 2, and the ASCO (American Society of Clinical Oncology) annual meeting, June 2 – 6.   They will be connecting with investors and clinical experts to discuss how Immunophotonics continues to...

Swiss Biotech Day 2023 April 24 & 25

Immunophotonics is pleased to announce its participation at the Swiss Biotech Day in Basel, Switzerland where VP of Business Development Theresa Visarius will present initial clinical and translational data on the use of IP-001 in solid tumor indications on April 24th in the Clinical Stage Development Companies session.

European Conference on Interventional Oncology (ECIO 2023) April 16 – 19

Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Booth 10 at the European Conference on Interventional Oncology (ECIO 2023) in Stockholm, Sweden, on April 16 – 19.  They are looking forward to connecting with clinical experts and learning from their experiences, as well as discussing how Immunophotonics continues...

Indian Patent Office Issues Patent Covering Immunophotonics’ Lead Drug Candidate, IP-001

Immunophotonics is excited to announce that its composition-of-matter patent has been granted by the Indian Patent Office (ISA/IPEA).  With this issuance, India has joined over 50 countries in granting Immunophotonics patent protection to the composition of matter underlying a range of polymers that encompasses the company’s lead drug candidate, IP-001.  Crucially, this latest patent allowance...

AngioDynamic International Life Symposium March 30 – April 1

Lu Alleruzzo, CEO & Co-Founder; and Tomas Hode, PhD, Co-Founder, CIO, & President were delighted to receive an invitation to attend the AngioDynamic International Life Symposium taking place in Rome, Italy, March 30 – April 1.  They will be connecting with clinical experts and industry partners from around the world and learning about the latest...

Immunophotonics Presenting at BIO CEO & Investor Conference February 6 – 9, 2023

Immunophotonics, Inc. is grateful to NCI (the National Cancer Institute of NIH) and its SBIR Investor Initiatives Team for sponsoring Immunophotonics to present its technology and novel approach to cancer treatment at the BIO CEO & Investor Conference taking place February 6 – 9, 2023 at the New York Marriot Marquis in New York City. ...

Immunophotonics Announces 1st Patient Dosed in IP-IIO-622 Phase 1b/2a Clinical Trial in Advanced Solid Tumor Indications

Immunophotonics, Inc. announced the initiation of recruitment and the dosing of its first patient in a clinical trial assessing safety and efficacy of its lead asset, IP-001, in multiple solid tumor indications.  This multinational clinical trial, denominated alternately as IP-IIO or INJECTABLE-1, is sponsored by Immunophotonics and will be enrolling patients for treatment of colorectal...

SIO Annual Scientific Meeting, January 19 – 23, 2023

Tomas Hode, PhD, Co-Founder, CIO, and President at @Immunophotonics, Inc. will be attending the Society of Interventional Oncology (SIO) 2023 annual scientific meeting January 19 – 23, in Washington, DC.  Tomas will be connecting with interventional oncology professionals from around the world and learning about the latest developments in improving cancer care alongside medical, surgical...

Scroll to top